Safety and effectiveness outcomes of a 3-in-1 carotid stent delivery system show no major strokes at 30-day and one-year follow ups and significantly low rates of clinically driven target lesion revascularisation at two years.

Dr William Gray (Main Line Health, Pennsylvania, US) joins us to discuss the first European presentation of the two-year outcomes from PERFORMANCE II (NCT04201132; Contego Medical, Inc.), a pivotal, single-arm, open-label study investigating the safety and effectiveness of the 3-in-1 Neuroguard integrated embolic protection (IEP) system for carotid artery stenting. Comorbid, high-risk surgical patients with carotid artery stenosis were enrolled in the study from 40 clinical sites. The primary outcome measures were death, all stroke and myocardial infarction as well as ipsilateral stroke.

Interview Questions:
1. What is the importance behind the PERFORMANCE II study?
2. Could you tell us about the unique features of the 3-in-1 Neuroguard IEP system?
3. What was the study design and patient population?
4. What were the key findings?
5. What are your take-home messages?
6. What further research is needed in this area?

Recorded remotely from Pennsylvania, 2025.

Editors: Jordan Rance, Yazmin Sadik
Videographers: David Ben-Harosh, Oliver Miles, Tom Green

Support: This is an independent interview produced by Radcliffe Vascular.